Susan Shiff
Director/Board Member chez CARA THERAPEUTICS, INC.
Fortune : 46 809 $ au 31/03/2024
Profil
Susan Patricia Shiff is an Independent Director at CARA Therapeutics, Inc. She is also a Director at Merck Global Health Innovation Fund LLC, Synthace Ltd., and a Trustee at New Jersey Symphony Orchestra.
Previously, she served as a Senior Vice President at Merck & Co., Inc. from 2014 to 2021.
She also held positions as a Vice President at Pfizer Inc. and Teva Pharmaceutics.
In addition, she was the President of Ontada LLC from 2021 to 2023.
Dr. Shiff holds a doctorate degree from the University of California, Los Angeles and an MBA from Cornell University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CARA THERAPEUTICS INC
0,09% | 01/06/2023 | 51 438 ( 0,09% ) | 46 809 $ | 31/03/2024 |
Postes actifs de Susan Shiff
| Sociétés | Poste | Début |
|---|---|---|
| CARA THERAPEUTICS, INC. | Director/Board Member | 26/06/2020 |
Synthace Ltd.
 Synthace Ltd. Packaged SoftwareTechnology Services Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom. | Director/Board Member | 05/06/2018 |
Merck Global Health Innovation Fund LLC
 Merck Global Health Innovation Fund LLC Investment ManagersFinance Merck Global Health Innovation Fund LLC invests in companies located across the globe with focus on North America and Europe. The fund focuses on companies operating in the fields of healthcare services. It provides financing for early stage and growth stage capital requirements with an investment size of USD 5 - 10 million. | Director/Board Member | - |
| New Jersey Symphony Orchestra | Director/Board Member | - |
Anciens postes connus de Susan Shiff
| Sociétés | Poste | Fin |
|---|---|---|
| Ontada | President | 01/07/2023 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/03/2021 |
| Teva Pharmaceutics | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Formation de Susan Shiff
| University of California, Los Angeles | Doctorate Degree |
| Cornell University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| CARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
| New Jersey Symphony Orchestra | |
| Teva Pharmaceutics | |
Merck Global Health Innovation Fund LLC
Merck Global Health Innovation Fund LLC Investment ManagersFinance Merck Global Health Innovation Fund LLC invests in companies located across the globe with focus on North America and Europe. The fund focuses on companies operating in the fields of healthcare services. It provides financing for early stage and growth stage capital requirements with an investment size of USD 5 - 10 million. | Finance |
Synthace Ltd.
Synthace Ltd. Packaged SoftwareTechnology Services Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom. | Technology Services |
| Ontada |
